The growth in the historic period can be attributed to increasing infertility prevalence, clinical success of assisted reproduction, expansion of fertility clinics, adoption of hormonal stimulation therapies, improved reproductive awareness.
The growth in the forecast period can be attributed to delayed parenthood trends, rising demand for ivf cycles, technological advances in fertility drugs, growing healthcare access in emerging markets, favorable reimbursement expansion. Major trends in the forecast period include single injection ovarian stimulation protocols, rising ivf procedure volumes, shift toward patient friendly fertility treatments, improved controlled ovarian response outcomes, growth of long acting gonadotropins.
The rising prevalence of ovarian disorders is expected to drive growth in the elonva market. Ovarian disorders can result from hormonal imbalances, genetic mutations such as BRCA1 and BRCA2, polycystic ovary syndrome (PCOS), autoimmune conditions, environmental factors like toxin exposure, and lifestyle choices such as obesity and smoking. Elonva treats ovarian disorders by stimulating the ovaries to produce multiple follicles, thereby improving the chances of successful pregnancy in women experiencing fertility issues, including PCOS or unexplained infertility. For example, in 2024, the American Cancer Society, a US-based non-profit organization, reported 19,680 new ovarian cancer cases in the US, with 12,740 deaths. Consequently, the rising prevalence of ovarian disorders is expected to propel the elonva market.
The rising infertility rate is also expected to support growth in the elonva market. Infertility refers to the inability of individuals or couples to achieve pregnancy after 12 months or more of regular, unprotected sexual intercourse. Increasing infertility rates are primarily driven by delayed childbearing, lifestyle changes, exposure to environmental toxins, and health conditions such as obesity and diabetes. Elonva helps address infertility by improving ovarian stimulation with a single injection that encourages the ovaries to produce multiple follicles, enhancing the likelihood of a successful pregnancy for women undergoing assisted reproductive technologies such as in vitro fertilization (IVF). For example, in April 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 17.5% of the global adult population - roughly 1 in 6 individuals - faces infertility. Therefore, the rising infertility rate is expected to propel the elonva market.
A key trend in the elonva market is obtaining regulatory approvals to expand access for patients requiring assisted reproductive technologies. This strategy aims to meet the demand for advanced, targeted therapies for women facing fertility challenges. For instance, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, received European Commission approval for Elonva, indicated for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART). This approval allows for uniform labeling across all European Union member states, simplifying access for healthcare providers and patients. Elonva is notable for replacing the first seven daily injections of conventional follicle-stimulating hormone (FSH) with a single subcutaneous injection, significantly reducing the treatment burden for women seeking pregnancy.
Major companies operating in the elonva market are Merck & Co. Inc.
North America was the largest region in the elonva market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the elonva market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the elonva market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have impacted the elonva market by increasing costs associated with importing biologically derived active ingredients and specialized cold chain packaging materials. These effects are more pronounced across fertility treatment segments in europe and asia pacific regions where cross border pharmaceutical sourcing is common. Increased tariffs have placed pricing pressure on fertility clinics and hospital pharmacies. However, tariffs are also encouraging local manufacturing investments and regional supply chain optimization, supporting long term resilience of fertility drug supply.
The elonva market research report is one of a series of new reports that provides elonva market statistics, including elonva industry global market size, regional shares, competitors with a elonva market share, detailed elonva market segments, market trends and opportunities, and any further data you may need to thrive in the elonva industry. This elonva market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Elonva (corifollitropin alfa) is a fertility medication used in assisted reproductive treatments, such as in vitro fertilization (IVF), to stimulate the ovaries and encourage the growth of multiple follicles. Elonva is a long-acting formulation that requires only a single injection to initiate ovarian stimulation, reducing the need for daily hormone injections. This provides a more controlled and convenient approach, improving the chances of successful pregnancy in women facing fertility challenges.
The main clinical indications in the elonva market include in vitro fertilization (IVF), hypogonadotropic hypogonadism in adolescent males, and ovarian hyperstimulation syndrome (OHSS) management. IVF is a medical procedure designed to help individuals and couples conceive by fertilizing an egg with sperm outside the body in a laboratory. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, with end users including fertility clinics, hospitals, research institutes, and other healthcare settings.
The elonva market consists of sales of corifollitropin alfa injectable formulations and hormonal combination treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to delayed parenthood trends, rising demand for ivf cycles, technological advances in fertility drugs, growing healthcare access in emerging markets, favorable reimbursement expansion. Major trends in the forecast period include single injection ovarian stimulation protocols, rising ivf procedure volumes, shift toward patient friendly fertility treatments, improved controlled ovarian response outcomes, growth of long acting gonadotropins.
The rising prevalence of ovarian disorders is expected to drive growth in the elonva market. Ovarian disorders can result from hormonal imbalances, genetic mutations such as BRCA1 and BRCA2, polycystic ovary syndrome (PCOS), autoimmune conditions, environmental factors like toxin exposure, and lifestyle choices such as obesity and smoking. Elonva treats ovarian disorders by stimulating the ovaries to produce multiple follicles, thereby improving the chances of successful pregnancy in women experiencing fertility issues, including PCOS or unexplained infertility. For example, in 2024, the American Cancer Society, a US-based non-profit organization, reported 19,680 new ovarian cancer cases in the US, with 12,740 deaths. Consequently, the rising prevalence of ovarian disorders is expected to propel the elonva market.
The rising infertility rate is also expected to support growth in the elonva market. Infertility refers to the inability of individuals or couples to achieve pregnancy after 12 months or more of regular, unprotected sexual intercourse. Increasing infertility rates are primarily driven by delayed childbearing, lifestyle changes, exposure to environmental toxins, and health conditions such as obesity and diabetes. Elonva helps address infertility by improving ovarian stimulation with a single injection that encourages the ovaries to produce multiple follicles, enhancing the likelihood of a successful pregnancy for women undergoing assisted reproductive technologies such as in vitro fertilization (IVF). For example, in April 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 17.5% of the global adult population - roughly 1 in 6 individuals - faces infertility. Therefore, the rising infertility rate is expected to propel the elonva market.
A key trend in the elonva market is obtaining regulatory approvals to expand access for patients requiring assisted reproductive technologies. This strategy aims to meet the demand for advanced, targeted therapies for women facing fertility challenges. For instance, in January 2023, Merck & Co., Inc., a US-based pharmaceutical company, received European Commission approval for Elonva, indicated for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART). This approval allows for uniform labeling across all European Union member states, simplifying access for healthcare providers and patients. Elonva is notable for replacing the first seven daily injections of conventional follicle-stimulating hormone (FSH) with a single subcutaneous injection, significantly reducing the treatment burden for women seeking pregnancy.
Major companies operating in the elonva market are Merck & Co. Inc.
North America was the largest region in the elonva market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the elonva market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the elonva market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs have impacted the elonva market by increasing costs associated with importing biologically derived active ingredients and specialized cold chain packaging materials. These effects are more pronounced across fertility treatment segments in europe and asia pacific regions where cross border pharmaceutical sourcing is common. Increased tariffs have placed pricing pressure on fertility clinics and hospital pharmacies. However, tariffs are also encouraging local manufacturing investments and regional supply chain optimization, supporting long term resilience of fertility drug supply.
The elonva market research report is one of a series of new reports that provides elonva market statistics, including elonva industry global market size, regional shares, competitors with a elonva market share, detailed elonva market segments, market trends and opportunities, and any further data you may need to thrive in the elonva industry. This elonva market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Elonva (corifollitropin alfa) is a fertility medication used in assisted reproductive treatments, such as in vitro fertilization (IVF), to stimulate the ovaries and encourage the growth of multiple follicles. Elonva is a long-acting formulation that requires only a single injection to initiate ovarian stimulation, reducing the need for daily hormone injections. This provides a more controlled and convenient approach, improving the chances of successful pregnancy in women facing fertility challenges.
The main clinical indications in the elonva market include in vitro fertilization (IVF), hypogonadotropic hypogonadism in adolescent males, and ovarian hyperstimulation syndrome (OHSS) management. IVF is a medical procedure designed to help individuals and couples conceive by fertilizing an egg with sperm outside the body in a laboratory. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, with end users including fertility clinics, hospitals, research institutes, and other healthcare settings.
The elonva market consists of sales of corifollitropin alfa injectable formulations and hormonal combination treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Elonva Market Characteristics
3. Elonva Market Supply Chain Analysis
4. Global Elonva Market Trends and Strategies
5. Elonva Market Analysis of End Use Industries
7. Global Elonva Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Elonva Total Addressable Market (TAM) Analysis for the Market
9. Elonva Market Segmentation
10. Elonva Market Regional and Country Analysis
11. Asia-Pacific Elonva Market
12. China Elonva Market
13. India Elonva Market
14. Japan Elonva Market
15. Australia Elonva Market
16. South Korea Elonva Market
17. Western Europe Elonva Market
18. UK Elonva Market
19. Germany Elonva Market
20. France Elonva Market
21. Eastern Europe Elonva Market
22. North America Elonva Market
23. USA Elonva Market
24. Canada Elonva Market
25. South America Elonva Market
26. Middle East Elonva Market
27. Africa Elonva Market
29. Elonva Market Competitive Landscape and Company Profiles
32. Elonva Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Elonva Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses elonva market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for elonva? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The elonva market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Clinical Indication: In Vitro Fertilization (IVF); Hypogonadotropic Hypogonadism in Adolescent Males; Ovarian Hyperstimulation Syndrome (OHSS) Management2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Fertility Clinics; Hospitals; Research Institutes; Other End Users
Companies Mentioned: Merck & Co. Inc.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Elonva market report include:- Merck & Co. Inc.
